Today: 20 May 2026
South32 stock slips on metals pullback as ASX rises — what investors watch next
8 January 2026
1 min read

South32 stock slips on metals pullback as ASX rises — what investors watch next

SYDNEY, Jan 8, 2026, 17:56 AEDT — Market closed

  • South32 ended down 0.8% at A$3.81, lagging a firmer ASX 200
  • Base metals cooled, with copper and nickel sliding
  • Focus shifts to South32’s December-quarter report on Jan. 22 and half-year results on Feb. 12

South32 Ltd shares fell on Thursday, trailing a firmer Australian share market as miners eased. The diversified metals producer closed down 0.78% at A$3.81, while the S&P/ASX 200 ended up 0.29% and the materials sector slid 1.23%. South32 has traded between A$2.47 and A$3.87 over the past 52 weeks.

The drift came as base metals cooled after a sharp run. Copper was down about 3.4% and nickel fell 4.4%, while aluminium dropped 1.6%, Market Index data showed.

That pullback followed a burst of price action earlier in the week. A Morgan Stanley note pointed to tight supply in aluminium and said copper supply disruptions seen last year were spilling into 2026, with three-month copper on the London Metal Exchange touching $13,387.50 a metric ton on Tuesday.

Longer term, the copper story is not getting smaller. S&P Global said on Thursday that copper demand could rise 50% by 2040 to 42 million metric tons a year, and warned supply could fall short by more than 10 million tons annually without more recycling and mining. “Copper is the metal of electrification,” Dan Yergin, S&P’s vice chairman, told Reuters, while Carlos Pascual at S&P called defence demand “inelastic”. Reuters

South32 has also been in front of the market with routine equity-plan disclosures. In a Jan. 6 regulatory notice, the company reported the granting of 14,314,934 rights, the exercising of 276,656 rights and the lapsing of 715,626 rights.

But the set-up cuts both ways. South32 has said it expects to place the Mozal aluminium smelter in Mozambique into care and maintenance — a temporary shutdown with ongoing upkeep — by March 2026 after failing to secure a long-term power agreement, and flagged a one-time cost of about $60 million.

For now, the stock is behaving like a metals proxy with a company label on it. If copper and aluminium keep sliding, South32 can look heavy even without fresh company news. If the metals bounce, the market is quick to chase.

Stock Market Today

  • Intuit Shares Drop 2.4% Premarket After Job Cut Report
    May 20, 2026, 10:10 AM EDT. Intuit Inc shares fell 2.4% in premarket trading following Reuters reports that the company plans to cut 17% of its workforce. The move signals cost-cutting amid an uncertain economic environment impacting the tech sector. Job reductions aim to streamline operations and improve financial resilience. Intuit is a key player in financial software, known for products like TurboTax and QuickBooks. These layoffs reflect broader industry trends as firms adjust to shifting demand and macroeconomic pressures.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI
Previous Story

Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet
Next Story

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet

Go toTop